CL2023000728A1 - Compuestos y composiciones como inhibidores de sppl2a. - Google Patents

Compuestos y composiciones como inhibidores de sppl2a.

Info

Publication number
CL2023000728A1
CL2023000728A1 CL2023000728A CL2023000728A CL2023000728A1 CL 2023000728 A1 CL2023000728 A1 CL 2023000728A1 CL 2023000728 A CL2023000728 A CL 2023000728A CL 2023000728 A CL2023000728 A CL 2023000728A CL 2023000728 A1 CL2023000728 A1 CL 2023000728A1
Authority
CL
Chile
Prior art keywords
sppl2a
inhibitors
compositions
compounds
sppl2a inhibitors
Prior art date
Application number
CL2023000728A
Other languages
English (en)
Spanish (es)
Inventor
Trixi Brandl
Claus Ehrhardt
Robert Epple
Christian Markert
Pascal Rigollier
Juraj Velcicky
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2023000728A1 publication Critical patent/CL2023000728A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2023000728A 2020-09-17 2023-03-14 Compuestos y composiciones como inhibidores de sppl2a. CL2023000728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063079604P 2020-09-17 2020-09-17

Publications (1)

Publication Number Publication Date
CL2023000728A1 true CL2023000728A1 (es) 2023-12-15

Family

ID=77897680

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023000728A CL2023000728A1 (es) 2020-09-17 2023-03-14 Compuestos y composiciones como inhibidores de sppl2a.
CL2024001312A CL2024001312A1 (es) 2020-09-17 2024-04-29 Compuestos y composiciones como inhibidores de sppl2a.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024001312A CL2024001312A1 (es) 2020-09-17 2024-04-29 Compuestos y composiciones como inhibidores de sppl2a.

Country Status (30)

Country Link
US (1) US20230365571A1 (https=)
EP (2) EP4578451A3 (https=)
JP (2) JP7771172B2 (https=)
KR (1) KR20230069947A (https=)
AU (1) AU2021342783A1 (https=)
CA (1) CA3192763A1 (https=)
CL (2) CL2023000728A1 (https=)
CO (1) CO2023004646A2 (https=)
CR (1) CR20230142A (https=)
DK (1) DK4214210T3 (https=)
DO (1) DOP2023000055A (https=)
EC (1) ECSP23027092A (https=)
ES (1) ES3028668T3 (https=)
FI (1) FI4214210T3 (https=)
GE (2) GEAP202516217A (https=)
HR (1) HRP20250562T1 (https=)
HU (1) HUE071569T2 (https=)
IL (1) IL300953B1 (https=)
JO (1) JOP20230044A1 (https=)
LT (1) LT4214210T (https=)
MA (1) MA61557B1 (https=)
MD (1) MD4214210T2 (https=)
MX (1) MX2023003122A (https=)
PE (1) PE20231099A1 (https=)
PL (1) PL4214210T3 (https=)
PT (1) PT4214210T (https=)
RS (1) RS66874B1 (https=)
SI (1) SI4214210T1 (https=)
SM (1) SMT202500216T1 (https=)
WO (1) WO2022058902A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116947813A (zh) * 2023-07-06 2023-10-27 绍兴贝斯美化工股份有限公司 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法
US20250263416A1 (en) 2024-02-15 2025-08-21 Incyte Corporation SPPL2a INHIBITORS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
GB9612622D0 (en) 1996-06-17 1996-08-21 Zeneca Ltd Chemical process
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
JP2008545780A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 有機化合物
WO2015160772A1 (en) 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Tetrahydro-benzoimidazolyl modulators of tgr5

Also Published As

Publication number Publication date
DOP2023000055A (es) 2023-06-15
CO2023004646A2 (es) 2023-07-21
SI4214210T1 (sl) 2025-07-31
JP2023541475A (ja) 2023-10-02
MD4214210T2 (ro) 2025-10-31
HUE071569T2 (hu) 2025-09-28
EP4578451A3 (en) 2025-09-17
AU2021342783A9 (en) 2024-09-12
EP4578451A2 (en) 2025-07-02
KR20230069947A (ko) 2023-05-19
MX2023003122A (es) 2023-03-22
CN116615425A (zh) 2023-08-18
PT4214210T (pt) 2025-05-22
IL300953A (en) 2023-04-01
AU2021342783A1 (en) 2023-05-18
WO2022058902A1 (en) 2022-03-24
IL300953B1 (en) 2026-04-01
PL4214210T3 (pl) 2025-08-18
ECSP23027092A (es) 2023-06-30
JP2026041723A (ja) 2026-03-10
JOP20230044A1 (ar) 2023-02-27
CR20230142A (es) 2023-08-25
CA3192763A1 (en) 2022-03-24
EP4214210B1 (en) 2025-04-09
MA61557B1 (fr) 2025-05-30
SMT202500216T1 (it) 2025-07-22
HRP20250562T1 (hr) 2025-07-04
ES3028668T3 (en) 2025-06-19
GEAP202516217A (en) 2025-02-10
LT4214210T (lt) 2025-07-25
GEP20257771B (en) 2025-06-10
DK4214210T3 (da) 2025-06-10
RS66874B1 (sr) 2025-06-30
EP4214210A1 (en) 2023-07-26
JP7771172B2 (ja) 2025-11-17
PE20231099A1 (es) 2023-07-18
US20230365571A1 (en) 2023-11-16
CL2024001312A1 (es) 2024-10-11
FI4214210T3 (fi) 2025-05-26

Similar Documents

Publication Publication Date Title
AR119765A1 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
EP4227390A4 (en) COMPOSITION CONTAINING A REFRIGERANT FLUID
EP4262803A4 (en) Tetrahydropyridopyrimidine pan-kras inhibitors
EP4148096A4 (en) COMPOSITION
EP4094582A4 (en) COMPOSITION
PT3837256T (pt) Compostos e composições de ureia como inibidores de smarca2/brm-atpase
EP4328279A4 (en) COMPOSITION
EP4115893A4 (en) Anti-tumor composition
EP4279545A4 (en) COMPOSITION
EP4110478C0 (en) DISINFECTANT COMPOSITIONS
EP4313320A4 (en) ANTIPERSPIRANT COMPOSITION
EP4122326A4 (en) OXYGEN Scavenger COMPOSITION
CL2023000728A1 (es) Compuestos y composiciones como inhibidores de sppl2a.
EP3999039A4 (en) PRETOMANID COMPOSITIONS
EP3741814C0 (en) COMPOSITION
EP4372077A4 (en) AUTOPHAGY-ACTIVATING COMPOSITION
EP4337752C0 (en) COMPOSITION
EP4330366C0 (en) COMPOSITION
EP4281046C0 (en) NALTREXONE-BASED COMPOSITIONS
EP4256012C0 (en) COMPOSITION
EP4291042C0 (en) COMPOSITION DERIVED FROM OATS
EP4454715A4 (en) COMPOSITION
EP4403170A4 (en) COMPOSITION CONTAINING CARYOPHYLLENE
EP4393305A4 (en) COMPOSITION
EP4337751C0 (en) COMPOSITION